The development of highly effective and durable vaccines against the human malaria
parasites Plasmodium falciparum and P. vivax remains a key priority. Decades of endeavor …

Malaria is a vector-borne disease of global importance, with the vast majority of its life-
threatening cases caused by infection with Plasmodium falciparum parasites. Repeated …

Obtaining full-length antibody heavy-and light-chain variable regions from individual B cells
at scale remains a challenging problem. Here we use high-throughput single-cell B-cell …

Pfs25 is a malaria transmission-blocking vaccine antigen candidate, but its apparently
limited immunogenicity in humans has hindered clinical development. Here, we show that …

The efficient spread of malaria from infected humans to mosquitoes is a major challenge for
malaria elimination initiatives. Gametocytes are the only Plasmodium life stage infectious to …

Summary Pfs230 domain 1 (Pfs230D1) is an advanced malaria transmission-blocking
vaccine antigen demonstrating high functional activity in clinical trials. However, the …

Development of effective malaria vaccines requires delivery platforms to enhance the
immunogenicity and efficacy of the target antigens. This is particularly challenging for …

Background Transmission blocking vaccines targeting the sexual-stages of the malaria
parasite could play a major role to achieve elimination and eradication of malaria. The …

Immunotherapies are disease management strategies that target or manipulate components
of the immune system. Infectious diseases pose a significant threat to human health as …

Structure-based antibody and antigen design has advanced greatly in recent years, due not
only to the increasing availability of experimentally determined structures but also to …